Standardization of Reporting Urine Cytology: The Paris System (TPS)

Abstract
The aim of urinary cytology is to detect urothelial carcinoma that is clinically significant, namely high-grade urothelial carcinoma (HGUC). A program was set to standardize urine cytology reporting similar to the Bethesda System for Reporting Cervical Cytology and the Bethesda System for Reporting Thyroid Cytology during the 18th International Congress of Cytology in Paris in May 2013. Eminent cytopathologists, surgical pathologists, and urologists assembled and formed the Paris System Working Group with support from both the International Academy of Cytology and the American Society of Cytopathology. Committees were formed to discuss the existing controversies, questions, and published literature in the field of urinary tract (UT) cytology, aiming at forming an international consensus on reporting UT specimens. In late 2015, the consensus group published their guidelines, known as The Paris System (TPS) for Reporting Urinary Cytology. TPS consists of 7 diagnostic categories and also tries to define several morphological criteria. This article tries to summarize and highlight essential points of The Paris System.

Keywords: The paris system; Urine cytology; Urothelial carcinoma

Abbreviations: HGUC: High-Grade Urothelial Carcinoma; UT: Urinary Tract; TPS: The Paris System; N/C: Nuclear Cytoplasmic Ratio; SHGUC: Suspicious for High Grade Urothelial Carcinoma; LGUN: Low Grade Urothelial Neoplasia

Introduction
For any reporting system to be successful and be applied in daily practice, it must be based on consensus, evidence, inclusion, acceptance, and understanding [1]. The main goal of urinary cytology is the detection of urothelial carcinoma that is clinically significant, namely high-grade urothelial carcinoma (HGUC). Therefore, the understanding of this disease, and particularly its pathogenesis, was crucial in the process of creating The Paris System for Reporting Urinary Cytology. A program to address standardization of urine cytology reporting similar to the Bethesda System for Reporting Cervical Cytology and the Bethesda System for Reporting Thyroid Cytology was conceived at the 18th International Congress of Cytology in Paris in May 2013 where eminent cytopathologists, surgical pathologists, and urologists assembled and formed the Paris System Working Group with support from both the International Academy of Cytology and the American Society of Cytopathology. Committees were formed to discuss the existing controversies, questions, and published literature in the field of urinary tract (UT) cytology, aiming at forming an international consensus on reporting UT specimens. In late 2015, the consensus group published their guidelines, known as The Paris System (TPS) for Reporting Urinary Cytology [2].

Discussion
TPS categories are as follows:

I. Non-diagnostic or Unsatisfactory,
II. Negative for High Grade Urothelial Carcinoma,
III. Atypia,
IV. Suspicious for High Grade Urothelial Carcinoma,
V. Low Grade Urothelial Neoplasia (LGUN),
VI. High Grade Urothelial Carcinoma (HGUC),
VII. Other malignancies, primary and metastatic [3-5].

Non-diagnostic or unsatisfactory
It was decided in The Paris System that any sample with atypical, suspicious, or malignant cells should be called adequate and reported. So the question of inadequacy comes only when the sample does not show any findings indicative of any disease process. Studies on volume, types of sample, sampling method, and cellularity of urine samples are limited and conclusions are varied [5]. There is a common misperception that cells in body fluids are solutes in a homogeneous solution. However, urine is a heterogeneous mixture of non-solute particulates: crystals, microorganisms, decaying cell remnants, and cells. It is heterogeneous because the particulates are not evenly distributed throughout the volume. Cells are denser than most aqueous solutions, so they sink. If only the supernatant, which is acellular or paucicellular, is examined because the first drops of a urine stream were not captured in the specimen container or because the specimen was inadvertently decanted, the results will be suboptimal [6]. It has also been stated that if urothelial cells are obscured by any inflammation, blood, mucus, lubricant etc., then the sample should be called inadequate. TPS has proposed that in instrumented specimens, 2600 cells or at least 20 cells in 10 HPF may be taken as adequacy criteria. So when there are 10-20 cells/10 HPF should be reported as “satisfactory but limited
by low cellularity" and those with <10 cells/10 HPFs should be
under "unsatisfactory/non diagnostic"[5].

Negative for high grade urothelial carcinoma

Because TPS acknowledges that UT cytopathology has a
poor sensitivity for detecting LGUN, the benign category does
not exclude the presence of LGUN. Instead, the benign category
indicates that a specimen does not contain HGUC cells, or any
cells with features concerning for HGUC, as defined by the criteria
below. A certain number of false-negatives is expected, especially
in voided urine samples which require tumour cells to be shed
into the urine before they can be diagnosed. Serial samples may
improve sensitivity for detection [7].

Atypia (atypical urothelial cells, AUC)

For a diagnosis of AUC, the sine qua non criterion is high
nuclear cytoplasmic ratio (N/C) (>0.5) in non-superficial
and non-degenerated urothelial cells. In addition, one of the
following criteria must also be present: mild to moderate nuclear
hyperchromasia (compared with a benign urothelial cell or a
squamous cell, used as an internal control), irregular nuclear
membranes (chromatinoic rim or nuclear contour), and irregular,
coarse chromatin pattern. To date, patients with a diagnosis of
AUC have been managed in a manner similar to patients assigned
a "negative" diagnosis. With the refocus by the Paris System on
relative risk of all categories predicting HGUC, and clear criteria
provided for the diagnosis of AUC, the hope is that the "atypia" rate
of urinary cytology will be reduced universally. As this concept
becomes more accepted worldwide, a shift in the management
strategy of AUC will inevitably follow, perhaps requiring a much
closer follow-up and evaluation of patients carrying this diagnosis
[5].

Suspicious for high grade urothelial carcinoma,
(SHGUC)

The suspicious category is meant to be the equivalent of similar
categories in other reporting systems, including the terminology
‘can not exclude high-grade urothelial carcinoma’. Overall, the
suspicious category is meant to imply a high risk of HGUC and
used in instances in which an unequivocal diagnosis of HGUC
cannot be made as a result of degenerative changes, a suboptimal
number of HGUC cells, or atypical cells which do not fulfill all the
criteria of the HGUC category.

The criteria for the SHGUC category are:

I. High N/C ratio. Atypical cells should have an N/C ratio of at
least 0.5.

II. Moderate-to-severe hyperchromasia.

Additionally, one of the following two features must be present:

I. Markedly, irregular nuclear borders.

II. Coarse, clumpy chromatin.

The quantity of cells is not important; a single cell meeting the
above criteria can qualify for an SHGUC diagnosis [8].

Low grade urothelial neoplasia, (LGUN)

LGUN includes all low-grade urothelial neoplasms of the
urinary tract, such as low-grade urothelial carcinoma and papillary
urothelial neoplasm of uncertain malignant potential. Under most
circumstances, atypical features not associated with HGUC can be
classified as benign (NHGUC) without concern for ‘missing’ a low-
grade neoplasm. However, if true papillary fragments are seen in
a specimen (thus indicating the presence of a papillary neoplasm)
and features of HGUC are absent, TPS allows for a diagnosis of
LGUN to be made [9].

High grade urothelial carcinoma (HGUC)

The number of atypical urothelial cells is an important
criterion to classify urine cytology specimens into the ‘positive’ or
the ‘suspicious’/AUC-H categories. A cut off number of >10 cells
in voided urine samples which require tumour cells to be shed
into the urine before they can be diagnosed. Serial samples may
improve sensitivity for detection [7].

Other malignancies, primary and metastatic

Primary bladder malignancies other than of urothelial origin
(nonurothelial carcinoma) comprise less than 5% of all bladder
and squamous cell carcinoma, adenocarcinoma, small cell carcinoma, leimyosarcoma, angiosarcoma, melanoma, hematologic malignancy etc. Their cytology features are similar as in other sites. Secondary carcinomas are mostly direct
invasion from surrounding organs as prostate, cervix, uterus,
gastrointestinal tract or metastasis from distant sites like
melanoma, carcinomas from kidney, breast, stomach, lung etc [5].

Conclusion

The intention of The Paris Working Group is to provide a
standardized guideline for reporting urine cytology. Hopefully The
Paris System will be universally accepted by the cytopathologists.
The Working Group with its ongoing studies will provide further
evidence based information in future especially on relative risk
and management protocol in each category as well as on ancillary
tests.

References

in diagnostic cytopathology: history, evolution, applicability and future.

Reporting Urinary Cytology. (1st edn), Springer, USA.

Cytopathology. Advances in bladder and prostatic tumors, Egyptian
society of pathology conference, Cairo, Egypt.


al. (2015) Adequacy of Urine Specimens (Adequacy). In: Rosenthal,
Dorothy L, et al. (Eds.), The Paris System for Reporting Urinary
Cytology. Springer, USA, p. 5-11.

